Skip to content

Lung Point of Care Ultrasound to Guide Albumin Administration in Cirrhosis

Lung Point Of Care Ultrasond (L-Pocus)-Guided Administration Of Intravenous Albumin In Decompensated Cirrhosis: A Pilot, Open Label, Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07072572
Acronym
POCUS
Enrollment
72
Registered
2025-07-18
Start date
2023-03-01
Completion date
2024-11-14
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Ascites, Cirrhosis, Cirrhosis Advanced

Keywords

Albumin, Lung ultrasound

Brief summary

To guide the administration of intravenous albumin by lung ultrasound in decompensated cirrhosis.

Interventions

DRUGLower albumin dosage

A fixed dose of 35 grams of albumin on they one and day two.

Sponsors

Centro Medico Issemym
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Older than 18 years. * Decompensated cirrhosis * Indication for intravenous albumin use

Exclusion criteria

* Development of variceal hemorrage before the administration of albumin, respiratory failure previous to albumin use, or the presence of hepatocellular carcinoma

Design outcomes

Primary

MeasureTime frameDescription
Overall mortality at 30 days30 daysOverall mortality at 30 days

Secondary

MeasureTime frameDescription
Acute kidney injuryEvery 24 hours, during hospitalization, (assesed up to 28 days)Number of Participants with acute kidney injury, as defined by the KDIGO criteria, being KDIGO 1 an increment in serum creatinine over baseline values of 0.3 mg/dL, KDIGO 2-2.9 times over baseline, KDIGO 3, 3 times over baseline.
Resolution of SBPDay three of antibiotic treatment initiated for spontaneous bacterial peritonitis.Number of Participants with resolution of SBP: Defined as a reduction of 25% of WBC in ascites performed through check up paracentesis at day three.
Respiratory failureEvery 24 hours, during hospitalization, (assesed up to 28 days)Number of Participants with respiratory failure, as defined as a requirement of greater than 10/L min og supplemental oxygen, a SpO2 lower than 92% on room temperature or an arterial blood oxyen concentration (pO2) lower than 60 mmHg.
acute-on-chronic liver failureDuring hospitailization, (assesed up to 28 days)Number of Participants with development of acute on chronic liver failure, as defined by ther Ec-CLF criteria, which asses biochemical function of six organ systems: liver, kidney, brain, coagulation, circulation, and lungs. Each organ system is graded on a scale of 1 to 3, with higher scores indicating more severe organ dysfunction.
Total hospitalization time30 daysTotal hospitalization time
Development of variceal hemorrhageDuring hospitailization, (assesed up to 28 days)Number of Participants with development of variceal hemorrhage: Defined as upper GI bleeding due to gastroesophageal varices confirmed by endoscopy

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026